Literature DB >> 2107574

Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis.

G R Reyes1, M A Purdy, J P Kim, K C Luk, L M Young, K E Fry, D W Bradley.   

Abstract

Major epidemic outbreaks of viral hepatitis in underdeveloped countries result from a type of non-A, non-B hepatitis distinct from the parenterally transmitted form. The viral agent responsible for this form of epidemic, or enterically transmitted non-A, non-B hepatitis (ET-NANBH), has been serially transmitted in cynomolgus macaques (cynos) and has resulted in typical elevation in liver enzymes and the detection of characteristic virus-like particles (VLPs) in both feces and bile. Infectious bile was used for the construction of recombinant complementary DNA libraries. One clone, ET1.1, was exogenous to uninfected human and cyno genomic liver DNA, as well as to genomic DNA from infected cyno liver. ET1.1 did however, hybridize to an approximately 7.6-kilobase RNA species present only in infected cyno liver. The translated nucleic acid sequence of a portion of ET1.1 had a consensus amino acid motif consistent with an RNA-directed RNA polymerase; this enzyme is present in all positive strand RNA viruses. Furthermore, ET1.1 specifically identified similar sequences in complementary DNA prepared from infected human fecal samples collected from five geographically distinct ET-NANBH outbreaks. Therefore, ET1.1 represents a portion of the genome of the principal viral agent, to be named hepatitis E virus, which is responsible for epidemic outbreaks of ET-NANBH.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2107574     DOI: 10.1126/science.2107574

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  178 in total

1.  A virus discovery method incorporating DNase treatment and its application to the identification of two bovine parvovirus species.

Authors:  T Allander; S U Emerson; R E Engle; R H Purcell; J Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

2.  Identification of immunodominant and conformational epitopes in the capsid protein of hepatitis E virus by using monoclonal antibodies.

Authors:  M A Riddell; F Li; D A Anderson
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Expression, characterization, and immunoreactivities of a soluble hepatitis E virus putative capsid protein species expressed in insect cells.

Authors:  Y Zhang; P McAtee; P O Yarbough; A W Tam; T Fuerst
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

4.  Detection of immunoglobulin M antibodies to hepatitis E virus by class capture enzyme immunoassay.

Authors:  C Yu; R E Engle; J P Bryan; S U Emerson; R H Purcell
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

5.  Hepatitis E virus in cultivated cells.

Authors:  M S Balayan; T A Ivannikova; L I Panina; T M Orlova; N A Zamyatina
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

6.  Hepatitis E: Canada welcomes the world.

Authors:  B G Rosser
Journal:  Can J Infect Dis       Date:  1995-01

7.  A new Chinese isolate of hepatitis E virus: comparison with strains recovered from different geographical regions.

Authors:  S Yin; R H Purcell; S U Emerson
Journal:  Virus Genes       Date:  1994-09       Impact factor: 2.332

8.  Hepatitis e virus: current concepts and future perspectives.

Authors:  Harry R Dalton; Suzan D Pas; Richie G Madden; Annemiek A van der Eijk
Journal:  Curr Infect Dis Rep       Date:  2014-04       Impact factor: 3.725

Review 9.  Mortality and morbidity among military personnel and civilians during the 1930s and World War II from transmission of hepatitis during yellow fever vaccination: systematic review.

Authors:  Roger E Thomas; Diane L Lorenzetti; Wendy Spragins
Journal:  Am J Public Health       Date:  2013-01-17       Impact factor: 9.308

10.  Isolation of the novel agent from human stool samples that is associated with sporadic non-A, non-B hepatitis.

Authors:  N Deka; M D Sharma; R Mukerjee
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.